Abstract
Twelve hyperprolactinemic women were administered the α aminoergoline derivative, CU 32-085 (Sandoz, Inc., East Hannover, NJ), in order to determine its effect on prolactin (PRL) secretion. The mean pretreatment serum PRL level was 145.0 ± 11.5 ng/ml. Significant declines of serum PRL occurred with total daily doses of CU 32-085 of 0.1 to 0.5 mg (P <0.001). The magnitude of response to therapy was dose-related. In six patients, PRL levels were reduced to less than 25 ng/ml; this effect lasted at least 24 hours after intake of a single dose. In the other six patients, the response was less dramatic. No subjects developed adverse cardiovascular side effects. The results of this study demonstrate that CU 32-085 exhibits a clinically significant dopaminomimetic action on PRL secretion in hyperprolactinemic women.
Original language | English (US) |
---|---|
Pages (from-to) | 555-559 |
Number of pages | 5 |
Journal | Fertility and Sterility |
Volume | 48 |
Issue number | 4 |
DOIs | |
State | Published - 1987 |
Funding
Received November 14, 1986; revised and accepted June 10, 1987. *Supported in part by a grant-in-aid from Sandoz, Inc., National Institute of Health grant ST33AM07039 (Dr. Rodman), and United States Public Health Service grant RR 054 to the Clinical Research Center of Tufts-New England Medical Center. t Department of Obstetrics and Gynecology, UCLA Medical Center. :j: Division of Endocrinology, Department of Medicine, Tufts University School of Medicine and the New England Medical Center. § Present address: Center for Endocrinology, Metabolism, and Nutrition, Northwestern University Medical School, Chicago, Illinois. II Present address and reprint requests: R. Jeffrey Chang, M.D., Director, Division of Reproductive Biology and Medicine, Department of Obstetrics and Gynecology, University of California, Davis, School of Medicine, 1621 Alhambra Boulevard, Suite 2500, Sacramento, California 95816.
ASJC Scopus subject areas
- Obstetrics and Gynecology
- Reproductive Medicine